Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Talnetant vs Placebo vs Risperidone in Schizophrenia
NCT00103727Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talnetant in schizophrenia, sponsored by GSK. Started Dec 2004; status: completed.
02
Drugs
talnetant
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00103727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103727.